Skip to content

Evaluation of the effects of Coenzyme Q10 on the serum concentration of interleukin 6 and interleukin 33 in hemodialysis patients

Evaluation of the effects of Coenzyme Q10 on the serum concentration of interleukin 6 and interleukin 33 in hemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015061722637N2
Enrollment
130
Registered
2017-05-21
Start date
2017-02-25
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease (Hemodialysis). Chronic kidney disease, stage 5 Chronic uraemia End stage kidney disease: in allograft failure NOS on dialysis without dialysis or transplant

Interventions

Intervention 1: Intervention 1: CoQ10 100 mg oral capsules, Dosage: 100 mg once daily, Duration: Three months. Intervention 2: Intervention 2 (control group): No treatment, Duration: Three months.
Treatment - Drugs
Intervention 1: CoQ10 100 mg oral capsules, Dosage: 100 mg once daily, Duration: Three months
Intervention 2 (control group): No treatment, Duration: Three months

Sponsors

Vice chancellor for research, Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who are undergoing regular hemodialysis for at least 3 months will be entered. Exclusion criteria: Being in active infection phase, having autoimmune diseases, consuming immunosuppressive medications or warfarin, pregnancy, breast feeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum concentration of interleukin 6. Timepoint: At baseline and at the end of the study. Method of measurement: ELISA kit.;Serum concentration of interleukin 33. Timepoint: At baseline and at the end of the study. Method of measurement: ELISA kit.

Secondary

MeasureTime frame
Adverse effects. Timepoint: During the study. Method of measurement: Patients' report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Sharifi Negad

Kerman University of Medical Sciences

zahrasharifi12@yahoo.com+98 34 3132 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026